Gyrus Capital, a healthcare sector-focused private equity firm, completed the acquisition of the heart valve business of LivaNova, a healthcare solutions provider, for $73m. “The completion of the HV sale to Gyrus Capital allows LivaNova to optimize its portfolio and sharpen its focus on cardiovascular and neuromodulation, our two areas of excellence. We are now better positioned to accelerate growth in our core, dedicate resources toward executing promising pipeline opportunities, and enhance our operational excellence to best serve our patients and deliver maximum value to shareholders,” Damien McDonald, LivaNova Chief Executive Officer.